Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.79 USD
+1.79 (3.31%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $55.76 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 281 - 300 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are under review due to the departure from the firm of analyst
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Two Weeks of Dosing of Skeletal Muscle Activator in ALS Patients Supports Safety Profile
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Two Weeks of Dosing of Skeletal Muscle Activator in ALS Patients Supports Safety Profile
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Skeletal Muscle Activator Program in ALS Moves Forward With Riluzole Combination Cohort
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Skeletal Muscle Activator Program in ALS Moves Forward With Riluzole Combination Cohort
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q11 Update: ?357 Partnership Talks Advance - Multi-Dose Phase 2 Data in ALS by YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q11 Update: ?357 Partnership Talks Advance - Multi-Dose Phase 2 Data in ALS by YE11
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Course Correction to Prioritize the Lead Assets
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Course Correction to Prioritize the Lead Assets
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Market Outperform Rating and a 12-Month Target Price of $4.
Provider: RODMAN & RENSHAW, CO.
Analyst: NOCHOMOVITZ Y
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q1:11 Earnings and Updates Clinical Developments
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q4:10 Earnings and Updates Clinical Developments
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
357 PIIa Results in ALS Setting - Promising Initial Progress.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G